| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1749-6632.1992.TB24586.X |
| P8608 | Fatcat ID | release_mpopumtlerdtvavpvwhy5zwusu |
| P698 | PubMed publication ID | 1379014 |
| P2093 | author name string | McCann UD | |
| G. A. Ricaurte | |||
| U. D. McCann | |||
| P2860 | cites work | Aetiology of Parkinson's disease | Q28261357 |
| (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates | Q28307777 | ||
| Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons | Q34792272 | ||
| Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels | Q39097283 | ||
| The long-term effects of multiple doses of methamphetamine on neostriatal trypthophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities | Q39294320 | ||
| Reversible and irreversible phases of serotonin depletion by 4-chloroamphetamine | Q39743110 | ||
| Neurochemical analysis of cerebrospinal fluid | Q40097982 | ||
| L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats | Q41135971 | ||
| Long-term effects of chronic methamphetamine administration in rhesus monkeys | Q42197795 | ||
| Metabolism of [14C]methamphetamine in man, the guinea pig and the rat | Q42918800 | ||
| Long-term effects of continuous exposure to p-chloroamphetamine on central serotonergic mechanisms in mice | Q44168116 | ||
| 5-Hydroxytryptamine depletion in mesencephalic nuclei of rat brain following a single injection of p-chloroamphetamine | Q44327078 | ||
| Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine | Q44786278 | ||
| Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). | Q44874777 | ||
| Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine] | Q44896408 | ||
| Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse | Q45261240 | ||
| Tremor in MPTP-induced parkinsonism | Q46130176 | ||
| Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys | Q46393102 | ||
| Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs | Q46890344 | ||
| Orally administered MDMA causes a long-term depletion of serotonin in rat brain | Q48087407 | ||
| Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration | Q48088563 | ||
| MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons | Q48121118 | ||
| Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat. | Q48181902 | ||
| The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain | Q48309926 | ||
| Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys | Q48405246 | ||
| Dexfenfluramine neurotoxicity in brains of non-human primates | Q48609779 | ||
| Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine | Q48651814 | ||
| Long-term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain | Q48714037 | ||
| Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain | Q48968033 | ||
| MDMA (ecstasy) effects on cultured serotonergic neurons: evidence for Ca2(+)-dependent toxicity linked to release | Q49095882 | ||
| Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. | Q51183031 | ||
| Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. | Q51757758 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurotoxicity | Q3338704 |
| P304 | page(s) | 371-382 | |
| P577 | publication date | 1992-05-01 | |
| 1992-05-11 | |||
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Neurotoxic amphetamine analogues: effects in monkeys and implications for humans | |
| P478 | volume | 648 |
| Q35745285 | Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function |
| Q48502115 | Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems |
| Q81681918 | Acute inhalation exposure to vaporized methamphetamine causes lung injury in mice |
| Q41180408 | Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). |
| Q24291930 | Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor |
| Q43595265 | An "accidental" acute psychosis with ecstasy use. |
| Q35810076 | Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia |
| Q89126816 | Binge-like acquisition of α-pyrrolidinopentiophenone (α-PVP) self-administration in female rats |
| Q41694692 | Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners |
| Q51053111 | Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. |
| Q34996750 | Cognitive judgment bias in the psychostimulant-induced model of mania in rats |
| Q34467867 | Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits |
| Q34272766 | Designer drugs: how dangerous are they? |
| Q34648071 | Ecstasy (MDMA) and memory function: a meta-analytic update |
| Q37318873 | Ecstasy produces left ventricular dysfunction and oxidative stress in rats |
| Q31033315 | Ecstasy: are animal data consistent between species and can they translate to humans? |
| Q36875417 | Effects of a short-course MDMA binge on dopamine transporter binding and on levels of dopamine and its metabolites in adult male rats. |
| Q45936086 | Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. |
| Q30479705 | Fetal effects of psychoactive drugs |
| Q40983371 | Fragment C Domain of Tetanus Toxin Mitigates Methamphetamine Neurotoxicity and Its Motor Consequences in Mice |
| Q34420092 | History and future of the Multidisciplinary Association for Psychedelic Studies (MAPS). |
| Q35147689 | Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease |
| Q72483586 | Influence of naloxone upon motor activity induced by psychomotor stimulant drugs |
| Q43805376 | Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. |
| Q40362823 | MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. |
| Q40140901 | MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. |
| Q34098788 | Methamphetamine and HIV-1: potential interactions and the use of the FIV/cat model |
| Q42978670 | Methamphetamine and lentivirus interactions: reciprocal enhancement of central nervous system disease |
| Q34086076 | Methamphetamine dependence: medication development efforts based on the dual deficit model of stimulant addiction |
| Q44519185 | Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q49025983 | Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (-)-HY038. |
| Q28143940 | Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse |
| Q33536778 | Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction |
| Q35294724 | Neuroimaging in drug abuse. |
| Q44865152 | Neurotoxicity of methamphetamine and methylenedioxymethamphetamine |
| Q73329501 | New drugs of abuse |
| Q71826414 | On The Neurotoxicity of MDMA and Related Amphetamine Derivatives |
| Q64869820 | Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease |
| Q34448544 | Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users |
| Q44123284 | Preprotachykinin A gene expression after administration of 3,4-methylene dioxymethamphetamine (Ecstasy). |
| Q48302266 | Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage |
| Q74014790 | Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss |
| Q48456238 | Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin |
| Q37597604 | Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity |
| Q48826215 | Serotonin transporter antibodies: production, characterization, and localization in the brain |
| Q44453908 | Specific memory deficits in ecstasy users? The results of a meta-analysis |
| Q44019771 | Specific neurotoxicity of chronic use of ecstasy |
| Q89208062 | Striatal Reinnervation Process after Acute Methamphetamine-Induced Dopaminergic Degeneration in Mice |
| Q44247697 | Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA). |
| Q30341737 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). |
| Q38413900 | The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory |
| Q48149811 | The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain |
| Q48367150 | The effects of cocaine and the amphetamines on brain and behavior: a conference report |
| Q28069364 | The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies |
| Q51962585 | The ethics of conducting psychosis-inducing experiments. |
| Q23915139 | Vascular-directed responses of microglia produced by methamphetamine exposure: indirect evidence that microglia are involved in vascular repair? |
| Q33643608 | White-matter abnormalities in brain during early abstinence from methamphetamine abuse |
| Q44673936 | Why is parkinsonism not a feature of human methamphetamine users? |
Search more.